regional medical center: Rare Genetic Immune Disease XLP2 Examined

Selasa, 22 Mei 2012

Rare Genetic Immune Disease XLP2 Examined

Rare Genetic Immune Disease XLP2 Examined

Editor's Choice
Main Category: Immune System / Vaccines
Article Date: 22 May 2012 - 13:00 PDT

email to a friend Â

printer friendly Â

opinions Â <!--

rate article
Patient / Public: not yet rated

Healthcare Prof: not yet rated

Researchers have taken an important step in understanding a rare genetic immune disorder which affects male children. Using biochemical analyses, the team was able to map how the XIAP protein activates a vital component of the immune defense system, specifically the component that fights bacterial infections in the gastro-intestinal system.

The study, conducted by researchers at The Novo Nordisk Foundation Center for Protein Research at the University of Copenhagen, is published in Molecular Cell.

Mads Gyrd-Hansen, Associate Professor from The Novo Nordisk Foundation Center for Protein Research, explains:

"Our results are an important step on the way to understanding the very serious - but fortunately rare - genetic immune disorder called X-linked lymphoproliferative syndrome type 2 (XLP2), which affects male children.
The gastro-intestinal system can be viewed as a long tube running through the body, absorbing nutrients and water. The contact surface between the intestinal system and the rest of the body is protected by an efficient immune barrier that confines the bacteria to the intestine. This barrier is not intact in XLP2 patients, who thus lack the necessary bulwark, so to say, between bacteria and body."

The researchers found that individuals with XLP2 have genetic variations that destroy XIAP's ability to bind the signaling protein ubiquitin to other proteins. This process is crucial for activating the immune system and survival.

The team highlights that these results can also help cancer researchers.

Gyrd-Hansen said:

"Several pharmaceutical companies have developed drugs to act on IAP proteins, including XIAP, as part of cancer treatment. Several of the drugs are currently being tested in clinical trials for their efficacy in treatment of leukemia and other forms of cancer. It is therefore essential to know precisely which biological processes in the organism the treatment can potentially affect."

Gyrd-Hansen and his team, who have been collaborating with researchers in the UK, Germany and Australia for around 18 months, explained:

"International collaboration has made it possible - in a short time - to describe detailed molecular processes, to use the descriptions to create mouse models for further tests and thereafter to link the results of these tests to genetic mutations identified in patients."

Written By Grace Rattue
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today

Additional

References

Citations

"The Ubiquitin Ligase XIAP Recruits LUBAC for NOD2 Signaling in Inflammation and Innate Immunity"
Rune Busk Damgaard, Ueli Nachbur, Monica Yabal, Wendy Wei-Lynn Wong, Berthe Katrine Fiil, Mischa Kastirr, Eva Rieser, James Arthur Rickard, Aleksandra Bankovacki, Christian Peschel, Juergen Ruland, Simon Bekker-Jensen, Niels Mailand, Thomas Kaufmann, Andreas Strasser, Henning Walczak, John Silke, Philipp J. Jost and Mads Gyrd-Hansen
Molecular, May 2012, doi:10.1016/j.molcel.2012.04.014 Please use one of the following formats to cite this article in your essay, paper or report:

MLA

APA

Please note: If no author information is provided, the source is cited instead.

Add Your Opinion On This Article

'Rare Genetic Immune Disease XLP2 Examined'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

regional medical center

Selasa, 22 Mei 2012

Rare Genetic Immune Disease XLP2 Examined

Add Your Opinion On This Article

Tidak ada komentar:

Posting Komentar